![]() |
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NEUROPHARMACOLOGY
Pharmaceuticals Division, Central Nervous System Research (L.L., K.J., L.O., J.G.W., E.B., J.-L.M., M.C.H.) and Roche Center for Medical Genomics (C.A.M., H.B.), F. Hoffmann-La Roche Ltd., Basel, Switzerland; and Department of Biomedicine, Institute of Physiology, Pharmacenter, University of Basel, Basel, Switzerland (A.B., B.B.)
The recent identification of the trace amine-associated receptor (TAAR)1 provides an opportunity to dissociate the effects of trace amines on the dopamine transporter from receptor-mediated effects. To separate both effects on a physiological level, a Taar1 knockout mouse line was generated. Taar1 knockout mice display increased sensitivity to amphetamine as revealed by enhanced amphetamine-triggered increases in locomotor activity and augmented striatal release of dopamine compared with wild-type animals. Under baseline conditions, locomotion and extracellular striatal dopamine levels were similar between Taar1 knockout and wild-type mice. Electrophysiological recordings revealed an elevated spontaneous firing rate of dopaminergic neurons in the ventral tegmental area of Taar1 knock-out mice. The endogenous TAAR1 agonist p-tyramine specifically decreased the spike frequency of these neurons in wild-type but not in Taar1 knockout mice, consistent with the prominent expression of Taar1 in the ventral tegmental area. Taken together, the data reveal TAAR1 as regulator of dopaminergic neurotransmission.
Address correspondence to: Dr. Marius C. Hoener, Pharmaceuticals Division, Central Nervous System Research, Department PRDNP5 CH, Bldg. 70/331, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland. E-mail: marius.hoener{at}roche.com
This article has been cited by other articles:
![]() |
Z. Xie and G. M. Miller A Receptor Mechanism for Methamphetamine Action in Dopamine Transporter Regulation in Brain J. Pharmacol. Exp. Ther., July 1, 2009; 330(1): 316 - 325. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Maguire, W. A. E. Parker, S. M. Foord, T. I. Bonner, R. R. Neubig, and A. P. Davenport International Union of Pharmacology. LXXII. Recommendations for Trace Amine Receptor Nomenclature Pharmacol. Rev., March 1, 2009; 61(1): 1 - 8. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. W. Bredy and M. Barad Social modulation of associative fear learning by pheromone communication Learn. Mem., December 30, 2008; 16(1): 12 - 18. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Xie and G. M. Miller {beta}-Phenylethylamine Alters Monoamine Transporter Function via Trace Amine-Associated Receptor 1: Implication for Modulatory Roles of Trace Amines in Brain J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 617 - 628. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Xie, S. V. Westmoreland, and G. M. Miller Modulation of Monoamine Transporters by Common Biogenic Amines via Trace Amine-Associated Receptor 1 and Monoamine Autoreceptors in Human Embryonic Kidney 293 Cells and Brain Synaptosomes J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 629 - 640. [Abstract] [Full Text] [PDF] |
||||